| Ident. | Authors (with country if any) | Title |
|---|
| 000075 (2020) |
Wolfgang F. Richter [Suisse] ; Hans-Peter Grimm [Suisse] ; Marie-Hélène Gouy [Suisse] ; Susi S Gaard [Danemark] ; Caroline Kreuzer [Suisse] ; Uwe Wessels [Allemagne] ; Dragomir Draganov [Suisse] ; Chris Muenzer [Suisse] ; Tonio Hoche [Suisse] | Subcutaneous Site-of-Absorption Study with the Monoclonal Antibody Tocilizumab in Minipigs: Administration Behind Ear Translates Best to Humans. |
| 000151 (2020) |
Helga Ellingsgaard [Danemark] ; Eleonora Seelig [Suisse] ; Katharina Timper [Suisse] ; Michael Coslovsky [Suisse] ; Line Soederlund [Danemark] ; Mark P. Lyngbaek [Danemark] ; Nicolai J. Wewer Albrechtsen [Danemark] ; Arno Schmidt-Trucks Ss [Suisse] ; Henner Hanssen [Suisse] ; Walter O. Frey [Suisse] ; Kristian Karstoft [Danemark] ; Bente K. Pedersen [Danemark] ; Marianne Böni-Schnetzler [Suisse] ; Marc Y. Donath [Suisse] | GLP-1 secretion is regulated by IL-6 signalling: a randomised, placebo-controlled study. |
| 000200 (2020) |
Kim Lauper [Suisse] ; Denis Mongin [Suisse] ; Florenzo Iannone [Italie] ; Eirik K. Kristianslund [Norvège] ; Tore K. Kvien [Norvège] ; Dan C. Nordström [Finlande] ; Karel Pavelka [République tchèque] ; Manuel Pombo-Suarez [Espagne] ; Ziga Rotar [Slovénie] ; Maria J. Santos [Portugal] ; Catalin Codreanu [Roumanie] ; Galina Lukina [Russie] ; Sara L. Gale [États-Unis] ; Markus John [Suisse] ; Yves Luder [Suisse] ; Delphine S. Courvoisier [Suisse] ; Cem Gabay [Suisse] | Comparative effectiveness of TNF inhibitors and tocilizumab with and without conventional synthetic disease-modifying antirheumatic drugs in a pan-European observational cohort of bio-naïve patients with rheumatoid arthritis. |
| 000296 (2019) |
Boulos Haraoui [Canada] ; Gustavo Casado [Argentine] ; Lászl Czirják [Hongrie] ; Andrew Taylor [Australie] ; Lingli Dong [République populaire de Chine] ; Peter Button [Australie] ; Yves Luder [Suisse] ; Roberto Caporali [Italie] | Tocilizumab Patterns of Use, Effectiveness, and Safety in Patients with Rheumatoid Arthritis: Final Results from a Set of Multi-National Non-Interventional Studies. |
| 000300 (2019) |
Michael R. Bishop [États-Unis] ; Richard T. Maziarz [États-Unis] ; Edmund K. Waller [États-Unis] ; Ulrich J Ger [Autriche] ; Jason R. Westin [États-Unis] ; Joseph P. Mcguirk [États-Unis] ; Isabelle Fleury [Canada] ; Harald Holte [Norvège] ; Peter Borchmann [Allemagne] ; Christopher Del Corral [États-Unis] ; Ranjan Tiwari [Inde] ; Özlem Anak [Suisse] ; Rakesh Awasthi ; Lida Pacaud [États-Unis] ; Vadim V. Romanov [États-Unis] ; Stephen J. Schuster [États-Unis] | Tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma patients without measurable disease at infusion. |
| 000314 (2019) |
Hind Hashwah [Suisse] ; Katrin Bertram [Suisse] ; Kristin Stirm [Suisse] ; Anna Stelling [Suisse] ; Cheuk-Ting Wu [Suisse] ; Sabrina Kasser [Suisse] ; Markus G. Manz [Suisse] ; Alexandre P. Theocharides [Suisse] ; Alexandar Tzankov [Suisse] ; Anne Müller [Suisse] | The IL-6 signaling complex is a critical driver, negative prognostic factor, and therapeutic target in diffuse large B-cell lymphoma. |
| 000344 (2019) |
Christoph T. Berger [Suisse] ; Birke Rebholz-Chaves [Suisse] ; Mike Recher [Suisse] ; Tobias Manigold [Suisse] ; Thomas Daikeler [Suisse] | Serial IL-6 measurements in patients with tocilizumab-treated large-vessel vasculitis detect infections and may predict early relapses. |
| 000422 (2019) |
Christoph T. Berger [Suisse] ; Thomas Daikeler [Suisse] | Longitudinal versus cross-sectional IL-6 measurements in tocilizumab-treated GCA response to: 'Analysis of IL-6 measurement in GCA patients treated with tocilizumab should consider concomitant treatment with prednisone' by Samson et al. |
| 000425 (2019) |
Vivian P. Bykerk [États-Unis] ; Andrew J K. Östör [Australie] ; José Alvaro-Gracia [Espagne] ; Karel Pavelka [République tchèque] ; José Andrés Román Ivorra [Espagne] ; Michael T. Nurmohamed [Pays-Bas] ; Yves Luder [Suisse] ; Paris N M. Sidiropoulos [États-Unis] ; Jenny Devenport [États-Unis] ; Jean Sibilia [France] | Long-term safety and effectiveness of tocilizumab in patients with rheumatoid arthritis and inadequate responses to csDMARDs and/or TNF inhibitors: an open-label study close to clinical practice. |
| 000442 (2019) |
Maxime Ma Verhoeven [Pays-Bas] ; Marjolein Jh De Hair [Pays-Bas] ; Janneke Tekstra [Pays-Bas] ; Johannes Wj Bijlsma [Pays-Bas] ; Jacob M. Van Laar [Pays-Bas] ; Attila Pethoe-Schramm [Suisse] ; Michelle Ea Borm [Pays-Bas] ; Evert-Jan Ter Borg [Pays-Bas] ; Suzanne P. Linn-Rasker [Pays-Bas] ; Xavier M. Teitsma [Pays-Bas] ; Floris Pjg Lafeber [Pays-Bas] ; Johannes Wg Jacobs [Pays-Bas] ; Paco Mj Welsing [Pays-Bas] | Initiating tocilizumab, with or without methotrexate, compared with starting methotrexate with prednisone within step-up treatment strategies in early rheumatoid arthritis: an indirect comparison of effectiveness and safety of the U-Act-Early and CAMERA-II treat-to-target trials. |
| 000489 (2019) |
Ernest Choy [Royaume-Uni] ; Roberto Caporali [Italie] ; Ricardo Xavier [Brésil] ; Bruno Fautrel [France] ; Raimon Sanmarti [Espagne] ; Min Bao [États-Unis] ; Jenny Devenport [États-Unis] ; Attila Pethö-Schramm [Suisse] | Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis. |
| 000494 (2019) |
Maxime M A. Verhoeven [Pays-Bas] ; Janneke Tekstra [Pays-Bas] ; Paco M J. Welsing [Pays-Bas] ; Attila Pethö-Schramm [Suisse] ; Michelle E A. Borm [Pays-Bas] ; George A W. Bruyn [Pays-Bas] ; Reinhard Bos [Pays-Bas] ; Ed N. Griep [Pays-Bas] ; Ruth Klaasen [Pays-Bas] ; Jacob M. Van Laar [Pays-Bas] ; Floris P J G. Lafeber [Pays-Bas] ; Johannes W J. Bijlsma [Pays-Bas] ; Marjolein J H. De Hair [Pays-Bas] ; Johannes W G. Jacobs [Pays-Bas] | Effectiveness and safety over 3 years after the 2-year U-Act-Early trial of the strategies initiating tocilizumab and/or methotrexate. |
| 000687 (2018) |
Ernest Choy [Royaume-Uni] ; Roberto Caporali [Italie] ; Ricardo Xavier [Brésil] ; Bruno Fautrel [France] ; Raim N Sanmarti [Espagne] ; Min Bao [États-Unis] ; Corrado Bernasconi [Suisse] ; Attila Pethö-Schramm [Suisse] | Subcutaneous tocilizumab in rheumatoid arthritis: findings from the common-framework phase 4 study programme TOZURA conducted in 22 countries. |
| 000688 (2018) |
Ernest Choy [Royaume-Uni] ; Roberto Caporali [Italie] ; Ricardo Xavier [Brésil] ; Bruno Fautrel [France] ; Raim N Sanmarti [Espagne] ; Min Bao [États-Unis] ; Corrado Bernasconi [Suisse] ; Attila Pethö-Schramm [Suisse] | Subcutaneous tocilizumab in rheumatoid arthritis: findings from the common-framework phase 4 study programme TOZURA conducted in 22 countries. |
| 000730 (2018) |
Xavier M. Teitsma [Pays-Bas] ; Johannes W G. Jacobs [Pays-Bas] ; Paco M J. Welsing [Pays-Bas] ; Attila Pethö-Schramm [Suisse] ; Michelle E A. Borm [Pays-Bas] ; Jacob M. Van Laar [Pays-Bas] ; Floris P J G. Lafeber [Pays-Bas] ; Johannes W J. Bijlsma [Pays-Bas] | Radiographic joint damage in early rheumatoid arthritis patients: comparing tocilizumab- and methotrexate-based treat-to-target strategies. |
| 000740 (2018) |
Eva-Maria Didden [Suisse] ; Yann Ruffieux [Suisse] ; Noemi Hummel [Suisse] ; Orestis Efthimiou [Suisse] ; Stephan Reichenbach [Suisse] ; Sandro Gsteiger [Suisse] ; Axel Finckh [Suisse] ; Christine Fletcher [Royaume-Uni] ; Georgia Salanti [Suisse] ; Matthias Egger [Suisse] | Prediction of Real-World Drug Effectiveness Prelaunch: Case Study in Rheumatoid Arthritis. |
| 000789 (2018) |
Christoph T. Berger ; Mike Recher ; Thomas Daikeler [Suisse] | Interleukin-6 flags infection in tocilizumab-treated giant cell arteritis. |
| 000801 (2018) |
Xavier M. Teitsma [Pays-Bas] ; Johannes W G. Jacobs [Pays-Bas] ; Paco M J. Welsing [Pays-Bas] ; Pascal H P. De Jong [Pays-Bas] ; Johanna M W. Hazes [Pays-Bas] ; Angelique E A M. Weel [Pays-Bas] ; Attila Pethö-Schramm [Suisse] ; Michelle E A. Borm [Pays-Bas] ; Jacob M. Van Laar [Pays-Bas] ; Floris P J G. Lafeber [Pays-Bas] ; Johannes W J. Bijlsma [Pays-Bas] | Inadequate response to treat-to-target methotrexate therapy in patients with new-onset rheumatoid arthritis: development and validation of clinical predictors. |
| 000850 (2018) |
Sanjoy Ketan Paul [Australie] ; Olga Montvida [Australie] ; Jennie H. Best [États-Unis] ; Sara Gale [États-Unis] ; Attila Pethoe-Schramm [Suisse] ; Khaled Sarsour [États-Unis] | Effectiveness of biologic and non-biologic antirheumatic drugs on anaemia markers in 153,788 patients with rheumatoid arthritis: New evidence from real-world data. |
| 000856 (2018) |
Grant S. Schulert [États-Unis] ; Francesca Minoia [Italie] ; John Bohnsack ; Randy Q. Cron ; Soah Hashad [Libye] ; Isabelle Koné-Paut [France] ; Mikhail Kostik [Russie] ; Daniel Lovell [États-Unis] ; Despoina Maritsi [Grèce] ; Peter A. Nigrovic [États-Unis] ; Priyankar Pal [Inde] ; Angelo Ravelli [Italie] ; Masaki Shimizu [Japon] ; Valda Stanevicha [Lettonie] ; Sebastiaan Vastert [Pays-Bas] ; Andreas Woerner [Suisse] ; Fabrizio De Benedetti [Italie] ; Alexei A. Grom [États-Unis] | Effect of Biologic Therapy on Clinical and Laboratory Features of Macrophage Activation Syndrome Associated With Systemic Juvenile Idiopathic Arthritis. |
| 000865 (2018) |
Alison O'Mahony [États-Unis] ; Markus R. John [Suisse] ; Hannah Cho [États-Unis] ; Misato Hashizume [Suisse] ; Ernest H. Choy [Royaume-Uni] | Discriminating phenotypic signatures identified for tocilizumab, adalimumab, and tofacitinib monotherapy and their combinations with methotrexate. |
